Medivation Inc has been working with investment bank JPMorgan Chase & Co to handle interest from other companies in a potential acquisition, but it has no plans to sell itself, according to people familiar with the matter.
The move is not uncommon in the healthcare industry. Biopharmaceutical companies such as Medivation are often approached by larger industry players. But acquisitions rarely happen without the target company cooperating.
Some of the approaches have taken place since the start of the year, the people said, without disclosing the names of the interested parties. The sources asked not to be identified because the matter is confidential.
Medivation did not immediately respond to a request for comment, while JPMorgan declined to comment.
Based in San Francisco, Medivation focuses on drugs for treating cancer. It has a market capitalization of $6.1 billion.
Sanofi SA, Roche Holding AG and AstraZeneca Plc are among the pharmaceutical companies that have expressed interest in acquiring drug makers in the United States.
Medivation has been under pressure from lawmakers, including Democratic Party presidential hopeful Bernie Sanders, a U.S. senator of Vermont, who criticized the high price of its only approved drug, Xtandi, which treats prostate cancer.
Beyond Xtandi, Medivation has a number of other potential cancer treatments in advanced stages of research and development.
The company’s stock has traded down more than 40 percent in the past year, in tandem with a broader selloff in the life sciences sector.
Earlier this week, Medivation hired Jennifer Jarrett as its new chief financial officer. She will replace Rick Bierly, who will retire in July.
By Carl O’Donnell and Greg Roumeliotis in New York
Source: Reuters
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.